Active — Not RecruitingNot Applicable

Clinical Impact of the IBox As an Early Intervention TooL

Austria, France507 participantsStarted 2022-02-18

Plain-language summary

International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by showing that the use of Predigraft could improve patient's follow-up.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women, age ≥ 18 years old at the time of consent. * Patients receiving a living or deceased donor kidney allograft. * Patients transplanted at least 3 months before inclusion. * Patients who signed the informed consent form and are willing to comply with study procedures. Exclusion Criteria: * Combined transplant (i.e. heart-kidney, liver-kidney). * Patients who are unable or unwilling to comply with study procedures. * Vulnerable patients (minors, protected adults, legally detained). * Patients participating in other interventional studies.

What they're measuring

number of biopsies leading to therapeutic change

Timeframe: 18 months

Trial details

NCT IDNCT05112315

SponsorPredict4Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02

View on ClinicalTrials.gov More Kidney Diseases trials